Jump to content

Atypical small acinar proliferation

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 02:38, 23 May 2016 (CS1 maintenance: vauthors/veditors or enumerate multiple authors/editors; WP:GenFixes on using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Atypical small acinar proliferation

In urologic pathology, atypical small acinar proliferation, abbreviated ASAP, is a collection of small prostatic glands, on prostate biopsy, whose significance is uncertain and cannot be determined to be benign or malignant.

ASAP, generally, is not considered a pre-malignancy, or a carcinoma in situ; it is an expression of diagnostic uncertainty,[1] and analogous to the diagnosis of ASCUS (atypical squamous cells of undetermined significance) on the Pap test.

Association with adenocarcinoma

On a subsequent biopsy, given the diagnosis of ASAP, the chance of finding prostate adenocarcinoma is approximately 40%; this is higher than if there is high-grade prostatic intraepithelial neoplasia (HGPIN).[2]

Management

ASAP is considered an indication for re-biopsy;[3] in one survey of urologists[4] 98% of respondents considered it a sufficient reason to re-biopsy.

See also

References

  1. ^ Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D (January 2007). "Atypical small acinar proliferation: biopsy artefact or distinct pathological entity". BJU International. 99 (4): 780–5. doi:10.1111/j.1464-410X.2006.06703.x. PMID 17378841.
  2. ^ Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M (June 2008). "Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy". Clinics. 63 (3): 339–42. doi:10.1590/S1807-59322008000300009. PMC 2664245. PMID 18568243.
  3. ^ Bostwick DG, Meiers I (July 2006). "Atypical small acinar proliferation in the prostate: clinical significance in 2006". Arch. Pathol. Lab. Med. 130 (7): 952–7. doi:10.1043/1543-2165(2006)130[952:ASAPIT]2.0.CO;2. PMID 16831049.
  4. ^ Rubin MA, Bismar TA, Curtis S, Montie JE (July 2004). "Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?". Am. J. Surg. Pathol. 28 (7): 946–52. doi:10.1097/00000478-200407000-00016. PMID 15223967.